Conde Sofia, Borrego Margarida, Teixeira Tânia, Teixeira Rubina, Corbal Maria, Sá Anabela, Soares Paula
Radiotherapy Department, Coimbra University Hospital, Portugal.
Oncology Department, Coimbra University Hospital, Portugal.
Rep Pract Oncol Radiother. 2010 May 20;15(3):51-9. doi: 10.1016/j.rpor.2010.04.002. eCollection 2010.
The impact of neoadjuvant chemotherapy (CT) and radiotherapy (RT) on overall survival (OS) has been controversial. Some studies have pointed to an improvement in OS and disease-free survival (DFS) in patients with pathologic complete response (pCR).
To evaluate the therapeutic response and impact on survival of preoperative RT, alone or combined with CT, in patients with locally advanced rectal cancer (LARC).
A set of 132 patients with LARC were treated preoperatively. GROUP 1: RT alone, 19 patients. GROUP 2: RT and concomitant oral CT (Capecitabine or UFT + leucovorin), 68 patients. GROUP 3: RT and concomitant CT with 5-FU in continuous infusion, 45 patients. 58.2% of patients were submitted to adjuvant CT.
GROUP 1: no pCR, tumoral downstaging was 26.7%. GROUP 2: pCR in 16.9%; tumoral downstaging was 47.7%. GROUP 3: pCR in 11.9%; tumor downstaging was 52.4%. The loco-regional control (LRC) was 95%. The 5-year OS (p = 0.038) and DFS (p = 0.05) were significantly superior in patients treated with CT + RT. Patients with pCR had a significant increase on DFS (p = 0.019). Patients cT3-4 that had a tumoral downstaging to ypT0-2, showed an increase on DFS, OS and LRC.
CT combined with RT has increased tumoral response and survival rate. Nodal downstaging and pCR were higher in the GROUP 2. The 5-year OS and DFS were significantly superior in CT + RT arms. Patients with pathologic response showed a better DFS. Adjuvant CT had no impact on LRC, DFS nor on OS.
新辅助化疗(CT)和放疗(RT)对总生存期(OS)的影响一直存在争议。一些研究指出,病理完全缓解(pCR)的患者总生存期和无病生存期(DFS)有所改善。
评估术前单纯放疗或放疗联合CT对局部晚期直肠癌(LARC)患者的治疗反应及生存影响。
对132例LARC患者进行术前治疗。第1组:单纯放疗,19例患者。第2组:放疗联合口服CT(卡培他滨或替加氟+亚叶酸钙),68例患者。第3组:放疗联合持续静脉输注5-FU的CT,45例患者。58.2%的患者接受辅助CT治疗。
第1组:无pCR,肿瘤降期率为26.7%。第2组:pCR为16.9%;肿瘤降期率为47.7%。第3组:pCR为11.9%;肿瘤降期率为52.4%。局部区域控制率(LRC)为95%。接受CT+RT治疗的患者5年总生存期(p = 0.038)和无病生存期(p = 0.05)显著更高。pCR患者的无病生存期显著增加(p = 0.019)。cT3-4期肿瘤降期至ypT0-2期的患者,无病生存期、总生存期和局部区域控制率均有所增加。
CT联合RT可提高肿瘤反应率和生存率。第2组的淋巴结降期和pCR更高。CT+RT组的5年总生存期和无病生存期显著更高。有病理反应的患者无病生存期更好。辅助CT对局部区域控制率、无病生存期和总生存期均无影响。